Table 1.

Patient characteristics

	pSS patients (N = 42)
Age (years)	62 (51; 68)
Sex (males/females)	2/40
Disease duration (years)	16 (7; 23)
Current/prior/never smokers (%)	20/41/39
Anti-SS-A antibody seropositives (%)	76
Anti-SS-B antibody seropositives (%)	48
ANA seropositives (%)	79
RF seropositives (%)	52
IgG (g/L)	13.1 (10.0; 17.1)
Complement component 3 (g/L)	1.00 (0.89; 1.15)
Complement component 4 (g/L)	0.16 (0.12; 0.21)
Lip biopsy—focus score ≥ 1 (N positives/N studied (%))	28/33 (85)
ESSDAI total score	6 (1; 12)
ESSPRI total score	6 (5; 8)
Fecal calprotectin (μg/g)	38 (20; 123)
Irritable bowel syndrome-like symptoms (%)	42
Using proton pump inhibitors (%)	36
Using NSAIDs (%)	38
Using glucocorticoids (%)	36
> 5 mg prednisolone daily	7
5 mg prednisolone daily	24
< 5 mg prednisolone daily	5
Using anti-malarials (%)	29
Using other DMARDs (%)	2

Demographic and clinical characteristics of the patients with primary Sjögren’s syndrome (pSS). Results presented as median (interquartile range) or percentage of subjects

DMARD disease-modifying anti-rheumatic drug, ESSDAI EULAR Sjögren’s Syndrome Disease Activity Index, ESSPRI EULAR Sjögren’s Syndrome Patient Reported Index, EULAR European League Against Rheumatism, NSAID nonsteroidal anti-inflammatory drug, ANA antinuclear antibodies, RF rheumatoid factor